Natural Plants Compounds as Modulators of Epithelial-to-Mesenchymal Transition

Epithelial-to-mesenchymal transition (EMT) is a self-regulated physiological process required for tissue repair that, in non-controled conditions may lead to fibrosis, angiogenesis, loss of normal organ function or cancer. Although several molecular pathways involved in EMT regulation have been desc...

Full description

Saved in:
Bibliographic Details
Main Authors: Lorena Avila-Carrasco (Author), Pedro Majano (Author), José Antonio Sánchez-Toméro (Author), Rafael Selgas (Author), Manuel López-Cabrera (Author), Abelardo Aguilera (Author), Guadalupe González Mateo (Author)
Format: Book
Published: Frontiers Media S.A., 2019-07-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_63e7d8b87dcd461784b94fe79fe84b4f
042 |a dc 
100 1 0 |a Lorena Avila-Carrasco  |e author 
700 1 0 |a Pedro Majano  |e author 
700 1 0 |a José Antonio Sánchez-Toméro  |e author 
700 1 0 |a José Antonio Sánchez-Toméro  |e author 
700 1 0 |a Rafael Selgas  |e author 
700 1 0 |a Rafael Selgas  |e author 
700 1 0 |a Manuel López-Cabrera  |e author 
700 1 0 |a Manuel López-Cabrera  |e author 
700 1 0 |a Abelardo Aguilera  |e author 
700 1 0 |a Abelardo Aguilera  |e author 
700 1 0 |a Guadalupe González Mateo  |e author 
700 1 0 |a Guadalupe González Mateo  |e author 
700 1 0 |a Guadalupe González Mateo  |e author 
245 0 0 |a Natural Plants Compounds as Modulators of Epithelial-to-Mesenchymal Transition 
260 |b Frontiers Media S.A.,   |c 2019-07-01T00:00:00Z. 
500 |a 1663-9812 
500 |a 10.3389/fphar.2019.00715 
520 |a Epithelial-to-mesenchymal transition (EMT) is a self-regulated physiological process required for tissue repair that, in non-controled conditions may lead to fibrosis, angiogenesis, loss of normal organ function or cancer. Although several molecular pathways involved in EMT regulation have been described, this process does not have any specific treatment. This article introduces a systematic review of effective natural plant compounds and their extract that modulates the pathological EMT or its deleterious effects, through acting on different cellular signal transduction pathways both in vivo and in vitro. Thereby, cryptotanshinone, resveratrol, oxymatrine, ligustrazine, osthole, codonolactone, betanin, tannic acid, gentiopicroside, curcumin, genistein, paeoniflorin, gambogic acid and Cinnamomum cassia extracts inhibit EMT acting on transforming growth factor-β (TGF-β)/Smads signaling pathways. Gedunin, carnosol, celastrol, black rice anthocyanins, Duchesnea indica, cordycepin and Celastrus orbiculatus extract downregulate vimectin, fibronectin and N-cadherin. Sulforaphane, luteolin, celastrol, curcumin, arctigenin inhibit β-catenin signaling pathways. Salvianolic acid-A and plumbagin block oxidative stress, while honokiol, gallic acid, piperlongumine, brusatol and paeoniflorin inhibit EMT transcription factors such as SNAIL, TWIST and ZEB. Plectranthoic acid, resveratrol, genistein, baicalin, polyphyllin I, cairicoside E, luteolin, berberine, nimbolide, curcumin, withaferin-A, jatrophone, ginsenoside-Rb1, honokiol, parthenolide, phoyunnanin-E, epicatechin-3-gallate, gigantol, eupatolide, baicalin and baicalein and nitidine chloride inhibit EMT acting on other signaling pathways (SIRT1, p38 MAPK, NFAT1, SMAD, IL-6, STAT3, AQP5, notch 1, PI3K/Akt, Wnt/β-catenin, NF-κB, FAK/AKT, Hh). Despite the huge amount of preclinical data regarding EMT modulation by the natural compounds of plant, clinical translation is poor. Additionally, this review highlights some relevant examples of clinical trials using natural plant compounds to modulate EMT and its deleterious effects. Overall, this opens up new therapeutic alternatives in cancer, inflammatory and fibrosing diseases through the control of EMT process. 
546 |a EN 
690 |a natural plants compounds 
690 |a epithelial-to-mesenchymal transition (EMT) 
690 |a anti-fibrotic 
690 |a anti-inflammatory 
690 |a anti-oxidant agent 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Frontiers in Pharmacology, Vol 10 (2019) 
787 0 |n https://www.frontiersin.org/article/10.3389/fphar.2019.00715/full 
787 0 |n https://doaj.org/toc/1663-9812 
856 4 1 |u https://doaj.org/article/63e7d8b87dcd461784b94fe79fe84b4f  |z Connect to this object online.